Elizaveta V. Ermolaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizaveta V. Ermolaeva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Petrovich Trashkov
NRC “Kurchatov Institute
2 shared publications - Andrey Glebovich Vasiliev
St. Petersburg State Pediatric Medical University
2 shared publications - A. P. Roytman
Russian Medical Academy of Continuing Professional Education
1 shared publication - A. V. Bugrov
Department of Clinical Laboratory Diagnostics of the Russian Medical Academy for Continuous Professional Education
1 shared publication - Alesya V. Soboleva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
1 shared publication - Alexander A. Lazutkin
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Science, Moscow 117485, Russia
1 shared publication
Latest Publications
- 1 June 2026
- Published by LLC Institute Information Technologies
AQPORINS IN THE PATHOGENESIS OF EXPERIMENTAL GLIOBLASTOMA
In the article, the authors examine the changes in the dynamics of aquaporin family protein accumulation in relation to the degree of development of human glioblastoma. During the experiment, a hypothesis was proposed regarding the uneven progression of the malignant neoplasm and the role of aquaporin family proteins in the accumulation of nutrients necessary for tumor growth.
- 1 June 2026
- Published by LLC Institute Information Technologies
AQPORINS IN THE PATHOGENESIS OF EXPERIMENTAL GLIOBLASTOMA
In the article, the authors examine the changes in the dynamics of aquaporin family protein accumulation in relation to the degree of development of human glioblastoma. During the experiment, a hypothesis was proposed regarding the uneven progression of the malignant neoplasm and the role of aquaporin family proteins in the accumulation of nutrients necessary for tumor growth.
- 30 December 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (4)
Laboratory predictors of severe course and prognosis of chronic heart failure in patients after COVID-19 recovery
Relevance. Coronavirus infection COVID-19 is associated with an increased risk of mortality among patients with cardiovascular diseases. COVID-19 directly and indirectly damages the myocardium, creating appropriate conditions for decompensation of chronic heart failure (CHF). In turn, cardiac disorders increase vulnerability to infection, creating a vicious cycle. Due to the increasing prevalence of CHF in the population, it is important to determine laboratory predictors of severe CHF and its prognosis in patients who have recovered from COVID-19, in order to improve risk stratification and optimize therapeutic strategies. Objective. To determine blood levels of biomarkers — soluble interleukin (IL)-33 receptor 2 (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL6)—in patients with CHF, who have recovered from COVID-19, and to evaluate the impact of the previous coronavirus infection on the course of CHF. Material and methods. Serum markers reflecting myocardial dysfunction (soluble sST2, NT-proBNP) and the presence of inflammation (hsCRP, IL-6) were measured in 77 patients. Patients were divided into four groups: based on the presence or absence of COVID-19 in anamnesis (groups 1 and 2, respectively) and based on the functional class of CHF, regardless of a history of COVID-19 (groups 3 and 4). The study was conducted using the AFIAS-6 immunofluorescence analyzer (Boditech Med Inc., Republic of Korea), provided by Avivir (Russia). Results. In the overall sample, regardless of the functional class of CHF, sST2 and NT-proBNP levels in patients who have not had COVID-19 in anamnesis, were significantly higher than in those with a history of COVID-19 (p<0.05). No statistically significant differences were found between hsCRP and IL-6 levels in the two groups (p=0.058 and p=0.7042, respectively). These results may indicate more intensive therapy in patients who have had coronavirus infection and the effect of therapeutic agents on the levels of the studied biomarkers. Then we divided patients into 2 groups by CHF functional class, regardless of their history of COVID-19. NT-proBNP levels were significantly higher in patients with CHF functional classes III-IV than in patients with CHF functional classes I-II (p<0.05). No statistically significant differences were found between hsCRP, IL-6, and sST2 levels (p=0.6096, p=0.705, and p=0.2642, respectively). Conclusion. COVID-19 does not significantly impact the cardiovascular system in patients with CHF (regardless of the functional class), as indicated by the levels of sST2 and NT-proBNP biomarkers. These results may be explained by the small sample size and more intensive therapy in patients who have recovered from COVID-19. Further studies, including those on a larger sample size, are needed due to the potential for long-term effects of COVID-19.
- 30 December 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (4)
Laboratory predictors of severe course and prognosis of chronic heart failure in patients after COVID-19 recovery
Relevance. Coronavirus infection COVID-19 is associated with an increased risk of mortality among patients with cardiovascular diseases. COVID-19 directly and indirectly damages the myocardium, creating appropriate conditions for decompensation of chronic heart failure (CHF). In turn, cardiac disorders increase vulnerability to infection, creating a vicious cycle. Due to the increasing prevalence of CHF in the population, it is important to determine laboratory predictors of severe CHF and its prognosis in patients who have recovered from COVID-19, in order to improve risk stratification and optimize therapeutic strategies. Objective. To determine blood levels of biomarkers — soluble interleukin (IL)-33 receptor 2 (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL6)—in patients with CHF, who have recovered from COVID-19, and to evaluate the impact of the previous coronavirus infection on the course of CHF. Material and methods. Serum markers reflecting myocardial dysfunction (soluble sST2, NT-proBNP) and the presence of inflammation (hsCRP, IL-6) were measured in 77 patients. Patients were divided into four groups: based on the presence or absence of COVID-19 in anamnesis (groups 1 and 2, respectively) and based on the functional class of CHF, regardless of a history of COVID-19 (groups 3 and 4). The study was conducted using the AFIAS-6 immunofluorescence analyzer (Boditech Med Inc., Republic of Korea), provided by Avivir (Russia). Results. In the overall sample, regardless of the functional class of CHF, sST2 and NT-proBNP levels in patients who have not had COVID-19 in anamnesis, were significantly higher than in those with a history of COVID-19 (p<0.05). No statistically significant differences were found between hsCRP and IL-6 levels in the two groups (p=0.058 and p=0.7042, respectively). These results may indicate more intensive therapy in patients who have had coronavirus infection and the effect of therapeutic agents on the levels of the studied biomarkers. Then we divided patients into 2 groups by CHF functional class, regardless of their history of COVID-19. NT-proBNP levels were significantly higher in patients with CHF functional classes III-IV than in patients with CHF functional classes I-II (p<0.05). No statistically significant differences were found between hsCRP, IL-6, and sST2 levels (p=0.6096, p=0.705, and p=0.2642, respectively). Conclusion. COVID-19 does not significantly impact the cardiovascular system in patients with CHF (regardless of the functional class), as indicated by the levels of sST2 and NT-proBNP biomarkers. These results may be explained by the small sample size and more intensive therapy in patients who have recovered from COVID-19. Further studies, including those on a larger sample size, are needed due to the potential for long-term effects of COVID-19.
- Open Access
- 28 March 2024
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 19 (1) , 61-84
Brain neurotrophic factor BDNF: new data, functions and questions
The brain-derived neurotrophic factor (BDNF) is a key modulator of neurogenesis, synaptogenesis, neuroregeneration, and cell differentiation in the nervous system. Impaired BDNF functioning is a characteristic of various neurological diseases, such as Alzheimer’s disease, multiple sclerosis, and depressive disorders. There is recent evidence that patients with COVID-19 have reduced BDNF levels in the blood plasma. Furthermore, exogenous BDNF and its mimetics have demonstrated therapeutic potential. In this review, we systematized data of the BDNF gene structure, epigenetic and microRNA-mediated regulation of its expression, transcriptional variants of BDNF, and the effects of BDNF on neuronal and oligodendroglial differentiation. Further, we point out the gaps in the current knowledge about BDNF and propose experiments that can expand such knowledge and the range of possibilities for using BDNF in biomedicine. These include determining the expression pattern of all BDNF gene transcripts at different stages of differentiation and in different cell subpopulations and studying the role of receptor-independent BDNF signaling, circadian fluctuations in BDNF levels, and their role in physiological and pathophysiological conditions. Finally, for translational medicine, evaluating the effect of BDNF mimetics (including those immobilized on three-dimensional scaffolds for tissue engineering) on neuronal and oligodendroglial differentiation of pluripotent and polypotent cells and identifying molecular regulators of BDNF transcription, including small molecules and microRNAs capable of regulating BDNF gene expression, are crucial.
- 28 March 2024
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 19 (1) , 61-84
Open AccessBrain neurotrophic factor BDNF: new data, functions and questions
The brain-derived neurotrophic factor (BDNF) is a key modulator of neurogenesis, synaptogenesis, neuroregeneration, and cell differentiation in the nervous system. Impaired BDNF functioning is a characteristic of various neurological diseases, such as Alzheimer’s disease, multiple sclerosis, and depressive disorders. There is recent evidence that patients with COVID-19 have reduced BDNF levels in the blood plasma. Furthermore, exogenous BDNF and its mimetics have demonstrated therapeutic potential. In this review, we systematized data of the BDNF gene structure, epigenetic and microRNA-mediated regulation of its expression, transcriptional variants of BDNF, and the effects of BDNF on neuronal and oligodendroglial differentiation. Further, we point out the gaps in the current knowledge about BDNF and propose experiments that can expand such knowledge and the range of possibilities for using BDNF in biomedicine. These include determining the expression pattern of all BDNF gene transcripts at different stages of differentiation and in different cell subpopulations and studying the role of receptor-independent BDNF signaling, circadian fluctuations in BDNF levels, and their role in physiological and pathophysiological conditions. Finally, for translational medicine, evaluating the effect of BDNF mimetics (including those immobilized on three-dimensional scaffolds for tissue engineering) on neuronal and oligodendroglial differentiation of pluripotent and polypotent cells and identifying molecular regulators of BDNF transcription, including small molecules and microRNAs capable of regulating BDNF gene expression, are crucial.
- 22 February 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (5) , 71-83
Circulating tumor RNA and exosomes as disease prognosis and therapy effectivity novel markers in case of malignant gliomas in adults
Malignant gliomas of CNS are the most wide-spread variant of primary brain tumors characteristic of invasive growth, fast evolution, high resistance to therapy and consequently quick recurrence that causes death of the patients. Taking into consideration peculiar features of these neoplasms an acute need has sprung in neurooncologic community for a search of novel low-invasive methods for the assessment of treatment effectivity and determining the progression rate of the disease. During the last decade a great number of studies exploring various circulating tumor ribonucleic acids in case of astrocytoma have been accomplished. The tumor nucleic acids as well as vesicles expressed by glioma may be discovered in blood and spine fluid. Thus these biomarkers are the most perspective targets for realizing these goals. The review presents tumor ribonucleic acids and exosomes, regulatory signaling pathways within tumor glioma cell causing resistance towards alkalizing chemical preparations and directly participating in recurrence. The most prospective nucleic acids as prognosis biomarkers and response to specific antitumor therapy predictors were determined and the most informative methods of their assessment have been depicted. Possibilities of alkalizing agents effectivity rise by means of nucleic acids expression correction have been discussed.
- 22 February 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 14 (5) , 71-83
Circulating tumor RNA and exosomes as disease prognosis and therapy effectivity novel markers in case of malignant gliomas in adults
Malignant gliomas of CNS are the most wide-spread variant of primary brain tumors characteristic of invasive growth, fast evolution, high resistance to therapy and consequently quick recurrence that causes death of the patients. Taking into consideration peculiar features of these neoplasms an acute need has sprung in neurooncologic community for a search of novel low-invasive methods for the assessment of treatment effectivity and determining the progression rate of the disease. During the last decade a great number of studies exploring various circulating tumor ribonucleic acids in case of astrocytoma have been accomplished. The tumor nucleic acids as well as vesicles expressed by glioma may be discovered in blood and spine fluid. Thus these biomarkers are the most perspective targets for realizing these goals. The review presents tumor ribonucleic acids and exosomes, regulatory signaling pathways within tumor glioma cell causing resistance towards alkalizing chemical preparations and directly participating in recurrence. The most prospective nucleic acids as prognosis biomarkers and response to specific antitumor therapy predictors were determined and the most informative methods of their assessment have been depicted. Possibilities of alkalizing agents effectivity rise by means of nucleic acids expression correction have been discussed.
- Open Access
Synthetic Thymidine Analog Labeling without Misconceptions
Tagging proliferating cells with thymidine analogs is an indispensable research tool; however, the issue of the potential in vivo cytotoxicity of these compounds remains unresolved. Here, we address these concerns by examining the effects of BrdU and EdU on adult hippocampal neurogenesis and EdU on the perinatal somatic development of mice. We show that, in a wide range of doses, EdU and BrdU label similar numbers of cells in the dentate gyrus shortly after administration. Furthermore, whereas the administration of EdU does not affect the division and survival of neural progenitor within 48 h after injection, it does affect cell survival, as evaluated 6 weeks later. We also show that a single injection of various doses of EdU on the first postnatal day does not lead to noticeable changes in a panel of morphometric criteria within the first week; however, higher doses of EdU adversely affect the subsequent somatic maturation and brain growth of the mouse pups. Our results indicate the potential caveats in labeling the replicating DNA using thymidine analogs and suggest guidelines for applying this approach.
Open AccessSynthetic Thymidine Analog Labeling without Misconceptions
Tagging proliferating cells with thymidine analogs is an indispensable research tool; however, the issue of the potential in vivo cytotoxicity of these compounds remains unresolved. Here, we address these concerns by examining the effects of BrdU and EdU on adult hippocampal neurogenesis and EdU on the perinatal somatic development of mice. We show that, in a wide range of doses, EdU and BrdU label similar numbers of cells in the dentate gyrus shortly after administration. Furthermore, whereas the administration of EdU does not affect the division and survival of neural progenitor within 48 h after injection, it does affect cell survival, as evaluated 6 weeks later. We also show that a single injection of various doses of EdU on the first postnatal day does not lead to noticeable changes in a panel of morphometric criteria within the first week; however, higher doses of EdU adversely affect the subsequent somatic maturation and brain growth of the mouse pups. Our results indicate the potential caveats in labeling the replicating DNA using thymidine analogs and suggest guidelines for applying this approach.